PL2090303T3 - Połączenie inhibitora prądu If węzła zatokowego i β-blokera - Google Patents

Połączenie inhibitora prądu If węzła zatokowego i β-blokera

Info

Publication number
PL2090303T3
PL2090303T3 PL09290099T PL09290099T PL2090303T3 PL 2090303 T3 PL2090303 T3 PL 2090303T3 PL 09290099 T PL09290099 T PL 09290099T PL 09290099 T PL09290099 T PL 09290099T PL 2090303 T3 PL2090303 T3 PL 2090303T3
Authority
PL
Poland
Prior art keywords
association
beta blocker
current inhibitor
sinus current
sinus
Prior art date
Application number
PL09290099T
Other languages
English (en)
Inventor
Guy Lerebours
Jean-Henri Calvet
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39666229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2090303(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PL2090303T3 publication Critical patent/PL2090303T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09290099T 2008-02-14 2009-02-12 Połączenie inhibitora prądu If węzła zatokowego i β-blokera PL2090303T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800800A FR2927538B1 (fr) 2008-02-14 2008-02-14 Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
EP09290099.2A EP2090303B1 (fr) 2008-02-14 2009-02-12 Association d'un inhibiteur du courant if sinusal et d'un bêta-bloquant

Publications (1)

Publication Number Publication Date
PL2090303T3 true PL2090303T3 (pl) 2013-07-31

Family

ID=39666229

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09290099T PL2090303T3 (pl) 2008-02-14 2009-02-12 Połączenie inhibitora prądu If węzła zatokowego i β-blokera

Country Status (38)

Country Link
US (1) US8217030B2 (pl)
EP (2) EP2409694A1 (pl)
JP (2) JP2009191069A (pl)
KR (1) KR101078133B1 (pl)
CN (1) CN101507726B (pl)
AP (1) AP2010005366A0 (pl)
AR (1) AR070416A1 (pl)
AU (1) AU2009200393B2 (pl)
BR (1) BRPI0900470A2 (pl)
CA (1) CA2654210C (pl)
CO (1) CO6290712A2 (pl)
CR (1) CR11628A (pl)
CU (1) CU24007B1 (pl)
CY (1) CY1114113T1 (pl)
DK (1) DK2090303T3 (pl)
EA (1) EA200900137A1 (pl)
EC (1) ECSP10010402A (pl)
ES (1) ES2421893T3 (pl)
FR (1) FR2927538B1 (pl)
GE (1) GEP20115261B (pl)
HK (1) HK1137341A1 (pl)
HN (1) HN2010001608A (pl)
HR (1) HRP20130617T1 (pl)
IL (1) IL207386A0 (pl)
MA (1) MA31132B1 (pl)
ME (1) ME01014B (pl)
MX (1) MX2009001590A (pl)
MY (1) MY149122A (pl)
NI (1) NI201000139A (pl)
NZ (1) NZ574843A (pl)
PL (1) PL2090303T3 (pl)
PT (1) PT2090303E (pl)
RS (1) RS52834B (pl)
SG (1) SG155130A1 (pl)
SI (1) SI2090303T1 (pl)
UA (1) UA99817C2 (pl)
WO (1) WO2009115669A1 (pl)
ZA (1) ZA200900894B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US9674435B1 (en) * 2016-07-06 2017-06-06 Lawrence Maxwell Monari Virtual reality platforms for capturing content for virtual reality displays
KR20190001340A (ko) * 2017-06-27 2019-01-04 에리슨제약(주) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503510A (ja) * 1989-11-21 1993-06-10 セプラカー・インコーポレーテツド 光学的に純粋な（ｓ）―アテノロールを含む組成物と方法
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
PT1362590E (pt) 2002-07-25 2004-05-31 Boehringer Ingelheim Pharma Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2894826B1 (fr) * 2005-12-21 2010-10-22 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur calcique et les compositions pharmaceutiques qui la contiennent
CN101095682A (zh) * 2007-07-23 2008-01-02 北京本草天源药物研究院 一种伊伐布雷定或其药用盐的口服制剂

Also Published As

Publication number Publication date
CN101507726A (zh) 2009-08-19
NZ574843A (en) 2011-07-29
ZA200900894B (en) 2009-12-30
US20090209515A1 (en) 2009-08-20
CY1114113T1 (el) 2016-07-27
CN101507726B (zh) 2012-03-28
IL207386A0 (en) 2010-12-30
KR20090088328A (ko) 2009-08-19
SG155130A1 (en) 2009-09-30
NI201000139A (es) 2011-01-10
HRP20130617T1 (en) 2013-07-31
RS52834B (en) 2013-10-31
GEP20115261B (en) 2011-08-10
US8217030B2 (en) 2012-07-10
ES2421893T3 (es) 2013-09-06
FR2927538B1 (fr) 2010-02-19
CU24007B1 (es) 2014-06-27
FR2927538A1 (fr) 2009-08-21
AU2009200393A1 (en) 2009-09-03
CA2654210A1 (fr) 2009-08-14
MX2009001590A (es) 2009-08-24
ME01014B (me) 2012-10-20
HK1137341A1 (en) 2010-07-30
MA31132B1 (fr) 2010-02-01
HN2010001608A (es) 2013-10-07
CA2654210C (fr) 2013-06-25
CU20100162A7 (es) 2011-10-31
UA99817C2 (ru) 2012-10-10
EP2090303A1 (fr) 2009-08-19
JP2012211179A (ja) 2012-11-01
SI2090303T1 (en) 2013-08-30
DK2090303T3 (da) 2013-07-29
BRPI0900470A2 (pt) 2009-09-29
EP2090303B1 (fr) 2013-05-01
MY149122A (en) 2013-07-15
PT2090303E (pt) 2013-05-31
AR070416A1 (es) 2010-04-07
AU2009200393B2 (en) 2013-11-07
ECSP10010402A (es) 2010-09-30
AP2010005366A0 (en) 2010-08-31
CO6290712A2 (es) 2011-06-20
EP2409694A1 (fr) 2012-01-25
KR101078133B1 (ko) 2011-10-28
EA200900137A1 (ru) 2009-10-30
WO2009115669A1 (fr) 2009-09-24
JP2009191069A (ja) 2009-08-27
CR11628A (es) 2010-11-22

Similar Documents

Publication Publication Date Title
HK1243713A1 (zh) 一種化合物的固體形式及其使用方法
EP2307440A4 (en) HEPARAN SULFATE INHIBITORS
IL230542B (en) Anti-inflammatory factors
PL2115324T3 (pl) Zespół trzpienia obrotowego i prowadnica do niego
EP1986584A4 (en) PROTECTION OF INJURY
ZA201008727B (en) Anti-inflammatory agents
EP2463316A4 (en) acrylate composition
EP2518041A4 (en) benzyl
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
EP2407476A4 (en) STEROID COMPOUND
EP2496788A4 (en) Core lifter
EP2383396A4 (en) RING FOR TAP
PL2262486T3 (pl) Kompozycja kwetiapiny
GB0918601D0 (en) Decahydro-1H-Indenoquinolinone and decahydro-3H-cyclopenaphenanthridinone CYP17 inhibitors
EP2254576A4 (en) ABLATENT AGENTS OF THE ANDROGEN RECEPTOR
GB2466042B (en) Voltage reduction
EP2262925A4 (en) CUTTING INSERT WITH OXIDE COVER
EP2123272A4 (en) ADAM INHIBITORS
SI2090303T1 (en) Association of a sinus current inhibitor if and a beta blocker
GB0903342D0 (en) Repositionable self-adhesive giftwrap
GB0922510D0 (en) Compound and use
TWM347748U (en) Core structure
EP2463286A4 (en) BENZYLPIPERIDINVERBINDUNG
PL385042A1 (pl) Przekładnik napięciowy
PL385043A1 (pl) Przekładnik napięciowy